This study examines United States real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns, duration, and adherence in mantle cell lymphoma (MCL) patients. A retrospective analysis of electronic medical records for patients with MCL who initiated a BTKi between January 2019 and November 2021 was conducted. Patients were followed ≥ 6 months, examining baseline characteristics and outcomes including treatment duration and adherence. 402 patients initiated acalabrutinib (n = 161), ibrutinib (n = 197), or zanubrutinib (n = 44). The zanubrutinib group demonstrated significantly longer median treatment duration (292 days) compared with acalabrutinib (259 days) and ibrutinib (149 days; P < 0.01) and displayed significantly higher adherence to treatment. In this study, zanubrutinib group experienced significantly longer treatment durations and higher adherence compared with the acalabrutinib and ibrutinib groups.
Shah et al. (Sun,) studied this question.